Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS. Hoekstra CJ, et al. Among authors: van tinteren h, van zandwijk n. J Clin Oncol. 2005 Nov 20;23(33):8362-70. doi: 10.1200/JCO.2005.01.1189. J Clin Oncol. 2005. PMID: 16293866 Clinical Trial.
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ. Smit EF, et al. Among authors: van zandwijk n. J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23. J Clin Oncol. 2009. PMID: 19307503 Clinical Trial.
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten Bokkel Huinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH. Huizing MT, et al. Among authors: van der vijgh wj, van warmerdam lj, van zandwijk n. J Clin Oncol. 1997 Jan;15(1):317-29. doi: 10.1200/JCO.1997.15.1.317. J Clin Oncol. 1997. PMID: 8996159 Clinical Trial.
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE. Giaccone G, et al. Among authors: van meerbeeck j, van hoesel q, van zandwijk n. J Clin Oncol. 1998 Jun;16(6):2133-41. doi: 10.1200/JCO.1998.16.6.2133. J Clin Oncol. 1998. PMID: 9626213 Clinical Trial.
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).
Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, Termeer A, Schlosser NJ, Debruyne C, Curran D, Giaccone G. Van Zandwijk N, et al. J Clin Oncol. 2000 Jul;18(14):2658-64. doi: 10.1200/JCO.2000.18.14.2658. J Clin Oncol. 2000. PMID: 10894864 Clinical Trial.
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, van Zandwijk N, van Tinteren H, Smit EF. Hoekstra CJ, et al. Among authors: van tinteren h, van zandwijk n. Lung Cancer. 2003 Feb;39(2):151-7. doi: 10.1016/s0169-5002(02)00446-4. Lung Cancer. 2003. PMID: 12581567
Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.
Kramer GW, Legrand CL, van Schil P, Uitterhoeve L, Smit EF, Schramel F, Biesma B, Tjan-Heijnen V, van Zandwijk N, Splinter T, Giaccone G, van Meerbeeck JP; EORTC-Lung Cancer Group. Kramer GW, et al. Among authors: van meerbeeck jp, van schil p, van zandwijk n. Eur J Cancer. 2006 Jul;42(10):1391-8. doi: 10.1016/j.ejca.2006.01.052. Eur J Cancer. 2006. PMID: 16785054 Clinical Trial.
274 results